Suppr超能文献

化疗耐药乳腺癌组织中的微小RNA表达模式

miRNA expression patterns in chemoresistant breast cancer tissues.

作者信息

Lv Jianxin, Xia Kai, Xu Pengfei, Sun Erhu, Ma Jingjing, Gao Sheng, Zhou Qian, Zhang Min, Wang Fengliang, Chen Fei, Zhou Ping, Fu Ziyi, Xie Hui

机构信息

Yangzhou Maternal and Child Health Hospital, Affiliated with Yangzhou Medical University, 225002 Yangzhou, China.

The Affiliated Jiangyin Hospital of Southeast University Medical College, 214400 Jiangyin, China.

出版信息

Biomed Pharmacother. 2014 Oct;68(8):935-42. doi: 10.1016/j.biopha.2014.09.011. Epub 2014 Oct 5.

Abstract

BACKGROUND/AIMS: Breast cancer chemoresistance is a major obstacle to the successful treatment of patients. miRNAs perform critical roles in biological processes, including tumorigenesis and chemoresistance. However, little clinical data are available regarding the relationship between miRNA expression patterns and breast cancer chemoresistance.

METHODS

We created a doxorubicin-resistant MCF-7 (MCF-/Adr) cell line using a pulse-selection method; then verified the resistance of the MCF-7/Adr cell line to doxorubicin by using the methyl thiazolyl tetrazolium (MTT) assay, terminal deoxyribonucleotidyl transferase (TdT)-mediated dUTP nick-end labeling (TUNEL) staining, and Intracellular doxorubicin accumulation assay. Then, we performed qRT-PCR to detect the expression patterns of 14 selected miRNAs (which are related to breast cancer resistance) in both cell lines. Subsequently, we performed a bioinformatics analysis, including Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) analyses, to determine the putative functions of 13 differentially expressed miRNA-targeted genes. Finally, we tested the expression levels of these 13 miRNAs in 10 chemotherapy non-responder breast cancer tissues and 29 responder tissues. All statistical analyses were performed by a two-tailed Student's t-test, and a P value less than 0.05 was considered statistically significant.

RESULTS

The results of the MTT assay showed that the MCF-7/Adr cell line was significantly more resistant to doxorubicin compared to the MCF-7 cells The results of the TUNEL assay indicated that doxorubicin induced an increase in the number apoptotic cells in the MCF-7 group. Additionally, the accumulation of doxorubicin was higher in MCF-7 cells compared to MCF-7/Adr cells, which was consistent with the MTT and TUNEL results. The qRT-PCR results demonstrated that compared to the parental MCF-7 cell line, miR-200a, miR-141, miR-200c, miR-31, miR-429, and miR-196b were over-expressed, and let-7e, miR-576-3p, miR-125b-1, miR-370, miR-145, miR-765, and miR-760 were significantly down-regulated in MCF-7/Adr cells. The GO analysis results revealed that the predicted target genes of these 14 miRNAs primarily regulated protein binding, zinc ion binding, DNA binding, and transcription factor activity. The KEGG data demonstrated that these target genes are mainly involved in the MAPK signaling pathway, regulation of the actin cytoskeleton, cytokine-cytokine receptor interaction, and other signaling pathways. Compared to the breast cancer tissues from chemotherapy responders, 10 miRNAs were identified to be dysregulated in the chemoresistant breast cancer tissues. Three of these miRNAs were up-regulated (miR-141, miR-200c, and miR-31), and 7 were down-regulated (let-7e, miR-576-3p, miR-125b-1, miR-370, miR-145, miR-765, and miR-760).

CONCLUSION

In this study, we identified 10 dysregulated miRNAs in both breast cancer cells and chemoresistant tissues, which might be biomarkers for the prognosis of breast cancer chemoresistance. Our study contributes to a comprehensive understanding of prognostic biomarkers during clinical treatment, and we hypothesize that the miRNA signatures of drug-resistant carcinoma tissues could be useful for developing new strategies for targeted therapies in patients with chemoresistant breast cancer.

摘要

背景/目的:乳腺癌化疗耐药是患者成功治疗的主要障碍。微小RNA(miRNA)在包括肿瘤发生和化疗耐药在内的生物学过程中发挥关键作用。然而,关于miRNA表达模式与乳腺癌化疗耐药之间的关系,临床数据较少。

方法

我们采用脉冲选择法建立了阿霉素耐药的MCF-7(MCF-7/Adr)细胞系;然后通过甲基噻唑基四氮唑(MTT)法、末端脱氧核苷酸转移酶(TdT)介导的dUTP缺口末端标记(TUNEL)染色和细胞内阿霉素积累试验,验证了MCF-7/Adr细胞系对阿霉素的耐药性。接着,我们进行qRT-PCR检测两种细胞系中14种选定的miRNA(与乳腺癌耐药相关)的表达模式。随后,我们进行了生物信息学分析,包括基因本体论(GO)和京都基因与基因组百科全书(KEGG)分析,以确定13个差异表达的miRNA靶向基因的推定功能。最后,我们检测了这13种miRNA在10例化疗无反应的乳腺癌组织和29例有反应的组织中的表达水平。所有统计分析均采用双尾Student's t检验,P值小于0.05被认为具有统计学意义。

结果

MTT试验结果表明,与MCF-7细胞相比,MCF-7/Adr细胞系对阿霉素的耐药性显著更高。TUNEL试验结果表明,阿霉素诱导MCF-7组凋亡细胞数量增加。此外,与MCF-7/Adr细胞相比,MCF-7细胞中阿霉素的积累更高,这与MTT和TUNEL结果一致。qRT-PCR结果表明,与亲本MCF-7细胞系相比,miR-200a、miR-141、miR-200c、miR-31、miR-429和miR-196b在MCF-7/Adr细胞中过表达,而let-7e、miR-576-3p、miR-125b-1、miR-370、miR-145、miR-765和miR-760显著下调。GO分析结果显示,这14种miRNA的预测靶基因主要调节蛋白质结合、锌离子结合、DNA结合和转录因子活性。KEGG数据表明,这些靶基因主要参与丝裂原活化蛋白激酶(MAPK)信号通路、肌动蛋白细胞骨架调节、细胞因子-细胞因子受体相互作用和其他信号通路。与化疗有反应者的乳腺癌组织相比,在化疗耐药的乳腺癌组织中鉴定出10种miRNA失调。其中3种miRNA上调(miR-141、miR-200c和miR-31),7种下调(let-7e、miR-576-3p、miR-125b-1、miR-370、miR-145、miR-765和miR-760)。

结论

在本研究中,我们在乳腺癌细胞和化疗耐药组织中均鉴定出10种失调的miRNA,它们可能是乳腺癌化疗耐药预后的生物标志物。我们的研究有助于全面了解临床治疗期间的预后生物标志物,并且我们推测耐药癌组织中的miRNA特征可能有助于为化疗耐药乳腺癌患者开发新的靶向治疗策略。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验